BioMarin Pharmaceutical 配当と自社株買い
配当金 基準チェック /06
BioMarin Pharmaceutical配当金を支払った記録がありません。
主要情報
n/a
配当利回り
0.4%
バイバック利回り
| 総株主利回り | 0.4% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
BMRN: Fair Value View Weighs Voxzogo Headwinds Against Amicus Acquisition Potential
Analysts have trimmed their average price target on BioMarin Pharmaceutical slightly, cutting fair value by about $0.30 to $55.36. They are factoring in a higher discount rate, modestly stronger long term growth and margins, and a slightly lower future P/E multiple following recent reassessments of the Voxzogo franchise and the planned Amicus acquisition.BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
Apr 15BMRN: Fair Value View Balances Voxzogo Risks And Amicus Opportunity
The analyst fair value estimate for BioMarin Pharmaceutical has been trimmed from about $60 to roughly $55.66 as analysts factor in a higher discount rate, a lower future P/E multiple, and mixed expectations around Voxzogo and the Amicus acquisition. Analyst Commentary Recent research on BioMarin reflects a mixed but generally constructive stance, with several firms revising price targets while keeping positive ratings.
BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks
Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged. Analyst Commentary Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures.BMRN: Amicus Acquisition Is Expected To Reshape Future Earnings Power
Analysts have nudged their fair value estimate for BioMarin to $88.96 from $88.65, citing updates to revenue growth, profit margin and future P/E assumptions as they reassess Voxzogo risks, competitive pressure and the potential impact of the Amicus acquisition. Analyst Commentary Recent street research paints a mixed picture for BioMarin, with analysts recalibrating expectations around Voxzogo, the Amicus acquisition and the broader rare disease portfolio.
BMRN: Rare Disease Portfolio Expansion And Amicus Acquisition Will Drive Repricing
Our BioMarin Pharmaceutical update trims the fair value estimate slightly to $120 from $122, as analysts weigh higher long term growth and margin assumptions against a higher discount rate and a lower future P/E multiple. Recent Street price target moves now cluster in the mid to high $90s, with outliers as low as $55 and as high as $105.BMRN: Recent Coverage Shifts Will Support Higher Future Earnings Multiple
Analysts have trimmed their fair value estimate for BioMarin Pharmaceutical by roughly $2 to about $88.65. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions drawn from recent Street research.BMRN: Shares Should Recover As Fresh Coverage Supports Higher Future Earnings Multiple
Analysts have lifted their price target for BioMarin Pharmaceutical by about US$1 to roughly US$91, citing updated assumptions around revenue growth, margins and a higher future P/E multiple, supported by recent positive Street research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Street coverage as support for using a higher future P/E multiple, which feeds directly into a slightly higher fair value range around US$91.BMRN: Reset Long Term Outlook Will Shape Risk Balance Going Forward
Analysts have reduced their price target on BioMarin Pharmaceutical to US$60 from US$67.39 as they factor in updated long term revenue scenarios, a higher discount rate, and slightly stronger margin assumptions following recent quarterly results and guidance changes. Analyst Commentary Recent Street research shows a cluster of price target cuts on BioMarin, generally following an "okay" Q3 print, a Q3 revenue miss in some areas, and updated long term guidance that now reflects a wider range of possible competitive and intellectual property outcomes.BMRN: Shares Should Recover As 2027 Revenue Reset Clarifies Competition Risk
Analysts now see fair value for BioMarin Pharmaceutical at $89.74 per share, a small move up that reflects lower long term revenue growth assumptions, a slightly higher profit margin outlook, and modestly higher future P/E expectations following recent price target cuts tied to Voxzogo trends, revised 2027 revenue guidance, and potential competition. Analyst Commentary Recent Street research shows a wide range of views on BioMarin, with a clear focus on Voxzogo trends, updated 2027 revenue scenarios, and the impact of potential competition on execution and valuation.BMRN: Shares Will Strengthen As 2025 Guidance Reset Supports Future Upside
Analysts have trimmed their average price target on BioMarin Pharmaceutical by roughly $1 to reflect a modest reset in long term revenue and margin expectations after Q3’s revenue miss, Voxzogo softness and greater acknowledgment of emerging competitive risks, even though they continue to view the shares as undervalued. Analyst Commentary Analyst reactions to BioMarin’s Q3 update reflect a more nuanced view of the company’s medium term growth profile, with reduced price targets but largely constructive ratings as investors recalibrate for competitive dynamics and updated long range guidance.BMRN: Shares Will Strengthen As 2025 Guidance and Pipeline Progress Drive Upside
BioMarin Pharmaceutical's analyst price target has been reduced from $90.50 to $89.36. Analysts cite slightly lower growth and profit margin expectations, new competitive pressures, and revised long-term guidance as key drivers for the change.BMRN: Shares Will Recover As Revenue Guidance Aligns With Market Expectations
Analysts have modestly reduced their price target for BioMarin Pharmaceutical, trimming it by $0.10 to $90.50. Recent updates reflect a more cautious outlook on revenue growth and profit margins in light of evolving competitive and regulatory expectations.BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead
Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
Oct 30
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 06Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Jul 22BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Jan 23Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15決済の安定と成長
配当データの取得
安定した配当: BMRNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: BMRNの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| BioMarin Pharmaceutical 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (BMRN) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Biotechs) | 2.6% |
| アナリスト予想 (BMRN) (最長3年) | 0% |
注目すべき配当: BMRNは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: BMRNは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: BMRNの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: BMRNが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/03 19:37 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
BioMarin Pharmaceutical Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。48
| アナリスト | 機関 |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Eliana Merle | Barclays |